Draft Medical Policies
BlueCross BlueShield of Tennessee


BlueCross BlueShield of Tennessee works to ensure that Medical Policies are developed in an open, collaborative manner with our providers. We invite you to submit comments during the development phase of our Medical Policies.


Medical policies are developed using an evidence-based evaluation process. The medical evidence used in this process comes from several sources, including independent medical technology review organizations, the peer reviewed medical literature, and expert opinions from BCBST network specialists. We especially welcome comments that include this type of information. All Medical Policies are reviewed and approved by a panel of BCBST Medical Directors as well as board certified network physicians before final adoption by the company.

Tracking Number

Medical Policy Name

Beginning of Comment Period

End of Comment Period

DMP0717-07 Noninvasive Techniques for Evaluation and Monitoring of Chronic Liver Diseases 07/19/17 08/19/17
DMP0717-08

Orthognathic Surgery

07/19/17 08/19/17
DMP0717-09

Cardioverter Defibrillators

07/20/17 08/20/17
DMP0817-01 Nivolumab 08/01/17 09/01/17
DMP0817-02 BRCA1, BRCA2 and PALB2 Testing for Breast, Ovarian and Other Cancers 08/02/17 09/02/17
DMP0817-03 Talimogene 08/14/17 09/14/17
DMP0817-04

Genetic Testing (CFTR-mutations) for Cystic Fibrosis

08/15/17 09/15/17

 


Medical Policy Comments:

Please reference the policy name or tracking number in your comments.
To submit comments about the draft Medical Policies:
Click the “Medical Policy Comments” above or click here: Comments or Feedback.

Comments can also be mailed to:

BlueCross BlueShield of Tennessee
Medical Policy
1 Cameron Hill Circle
Chattanooga, TN 37402